Neogenomics P/E Ratio

Neogenomics (NEO) currently reports a P/E ratio of -9.31. That is below the Healthcare sector average of 25.72. Use the charts on this page to explore Neogenomics's P/E ratio history and peer comparisons.

Neogenomics's P/E ratio of -9.31 is lower than the Healthcare sector average of 25.72. That is roughly 136.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Neogenomics's market price to a fundamental measure such as earnings, sales, or book value. At -9.31, NEO can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -9.31, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.72. From there, open related valuation or income-statement pages for Neogenomics, and consider following NEO for alerts when major investors trade the stock.

Neogenomics is classified in the Healthcare sector. On P/E ratio, it currently shows -9.31 versus a sector average near 25.72. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NEO with unrelated industries.